Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 12/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 11/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577986 | 1.00 | HDAC4 (1.00) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL1066988 | 0.89 | HDAC3 (0.81) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL1064977 | 0.86 | HDAC3 (0.78) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL8090513 | 0.86 | HDAC1 (1.00) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL1065479 | 0.86 | HDAC3 (0.78) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL23023795 | 0.85 | HDAC3 (0.76) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL30444964 | 0.85 | HDAC3 (0.76) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL18248585 | 0.85 | HDAC3 (0.76) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL14645344 | 0.85 | HDAC3 (0.76) | HDAC4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL13668924 | 0.84 | HDAC3 (0.73) | HDAC4HDAC1HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3006424-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | The Scripps Research Institute (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-1951656-B1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | SCRIPPS RESEARCH INST (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150080472-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-03-19 | — | — | US | disclosed |
| US-20150080472-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-03-19 | — | — | US | disclosed |
| US-8835502-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835502-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTUTE (US) | 2011-01-27 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007058927-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC4 2/4885HDAC1 1/4885HDAC11 6/4885 |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC4 2/4885HDAC1 1/4885HDAC11 6/4885 |
| US-20150080472-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC4 2/4885HDAC1 1/4885HDAC11 6/4885 |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | HDAC5, HDAC1, HDAC6 | HDAC4 5/4885HDAC1 2/4885HDAC11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.